

LA JOLLA PHARMACEUTICAL CO

Form 8-K

September 22, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): September 22, 2004

**La Jolla Pharmaceutical Company**

---

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	0-24274 (Commission File Number)	33-0361285 (IRS Employer Identification No.)
6455 Nancy Ridge Drive, San Diego, California (Address of principal executive offices)		92121 (Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

N/A

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01. Other Events.**

On September 22, 2004, La Jolla Pharmaceutical Company issued a press release announcing that Steven Engle, the Company's Chief Executive Officer, will present at the UBS Global Life Sciences Conference on September 30, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LA JOLLA PHARMACEUTICAL COMPANY**

Date: September 22, 2004

By: /s/ Steven B. Engle

---

Steven B. Engle  
Chairman and Chief Executive Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release